{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:18Z","timestamp":1793157438610,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.urolonc.2021.05.033","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T02:51:39Z","timestamp":1626576699000},"page":"834.e21-834.e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Yudai","family":"Ishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.urolonc.2021.05.033_bib0001","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2021.05.033_bib0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1756287218814100","article-title":"The continuing role of chemotherapy in the management of advanced urothelial cancer. Ther","volume":"10","author":"G\u00f3mez De Lia\u00f1o","year":"2018","journal-title":"Adv Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.05.033_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1016\/j.urolonc.2021.05.033_bib0004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"The Lancet"},{"issue":"10064","key":"10.1016\/j.urolonc.2021.05.033_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"The Lancet"},{"issue":"13","key":"10.1016\/j.urolonc.2021.05.033_bib0006","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.033_bib0007","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.033_bib0008","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2021.05.033_bib0009","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.21873\/anticanres.13765","article-title":"Neutrophil-to-lymphocyte ratio and use of antibiotics associated with prognosis in esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitors","volume":"39","author":"Guo","year":"2019","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.033_bib0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.urolonc.2021.05.033_bib0011","first-page":"1","article-title":"Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors","author":"Hwang","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.033_bib0012","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"issue":"10122","key":"10.1016\/j.urolonc.2021.05.033_bib0013","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.urolonc.2021.05.033_bib0014","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2020 doi:10.1016\/j.eururo.2020.03.055.","DOI":"10.1016\/j.eururo.2020.03.055"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.033_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.033_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2014.07.015","article-title":"The risk of urinary tract infection after flexible cystoscopy in patients with bladder tumor who did not receive prophylactic antibiotics","volume":"193","author":"Herr","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.033_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7164","key":"10.1016\/j.urolonc.2021.05.033_bib0018","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"issue":"6161","key":"10.1016\/j.urolonc.2021.05.033_bib0019","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.033_bib0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.033_bib0021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota - a systematic review","volume":"79","author":"Zimmermann","year":"2019","journal-title":"J. Infect."},{"key":"10.1016\/j.urolonc.2021.05.033_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.urolonc.2021.05.033_bib0023","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s00345-019-02737-3","article-title":"The risk factors of urinary tract infection after transurethral resection of bladder tumors","volume":"37","author":"Kohada","year":"2019","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.033_bib0024","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.ajkd.2005.09.008","article-title":"Urinary tract infections in patients with urinary diversion","volume":"46","author":"Falagas","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.033_bib0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tau.2019.07.12","article-title":"Urinary tract infections in patients undergoing radical cystectomy and urinary diversion: challenges and considerations in antibiotic prophylaxis","volume":"8","author":"Symeonidis","year":"2019","journal-title":"Transl Androl Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2021.05.033_bib0026","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/1060028019830785","article-title":"Effects of chemotherapy-induced neutropenia on overall survival in patients with unresectable or metastatic urothelial carcinoma to gemcitabine plus cisplatin combination chemotherapy","volume":"53","author":"Yamamoto","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.urolonc.2021.05.033_bib0027","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, et al. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2020 doi:10.1111\/cas.14762.","DOI":"10.1111\/cas.14762"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.033_bib0028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6371","key":"10.1016\/j.urolonc.2021.05.033_bib0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:56Z","timestamp":1761042236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1078143921002520"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.033","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}